Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1957 2
1959 2
1961 1
1965 2
1973 3
1974 5
1975 2
1977 2
1986 1
1987 2
1989 1
1990 2
1991 1
1992 2
1993 1
1994 2
1996 4
1997 4
1998 6
1999 9
2000 10
2001 13
2002 8
2003 12
2004 8
2005 7
2006 21
2007 14
2008 20
2009 20
2010 17
2011 26
2012 19
2013 22
2014 29
2015 21
2016 28
2017 31
2018 31
2019 31
2020 41
2021 57
2022 64
2023 63
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

615 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.
Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A. Casadei-Gardini A, et al. Among authors: masi g. Eur J Cancer. 2023 Feb;180:9-20. doi: 10.1016/j.ejca.2022.11.017. Epub 2022 Nov 25. Eur J Cancer. 2023. PMID: 36527976 Clinical Trial.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Bruix J, et al. Among authors: masi g. Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Lancet. 2017. PMID: 27932229 Clinical Trial.
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, Ambrosini M, Tamburini E, Tortora G, Passardi A, Bergamo F, Kassambara A, Sbarrato T, Morano F, Ritorto G, Borelli B, Boccaccino A, Conca V, Giordano M, Ugolini C, Fieschi J, Papadopulos A, Massoué C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Fontanini G, Boni L, Galon J, Cremolini C; GONO Foundation Investigators. Antoniotti C, et al. Among authors: masi g. Lancet Oncol. 2022 Jul;23(7):876-887. doi: 10.1016/S1470-2045(22)00274-1. Epub 2022 May 27. Lancet Oncol. 2022. PMID: 35636444 Clinical Trial.
In Reply.
Salani F, Ugolini C, Catanese S, Cacciato Insilla A, Fornaro L, Campani D, Vasile E, Fontanini G, Masi G, Vivaldi C. Salani F, et al. Among authors: masi g. Oncologist. 2021 Oct;26(10):e1895-e1896. doi: 10.1002/onco.13886. Epub 2021 Jul 17. Oncologist. 2021. PMID: 34176190 Free PMC article.
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Cremolini C, et al. Among authors: masi g. JAMA Oncol. 2019 Mar 1;5(3):343-350. doi: 10.1001/jamaoncol.2018.5080. JAMA Oncol. 2019. PMID: 30476968 Free PMC article. Clinical Trial.
Paraneoplastic neurological syndromes.
Iorio R, Spagni G, Masi G. Iorio R, et al. Among authors: masi g. Semin Diagn Pathol. 2019 Jul;36(4):279-292. doi: 10.1053/j.semdp.2019.06.005. Epub 2019 Jun 21. Semin Diagn Pathol. 2019. PMID: 31253539 Review.
615 results